Artelo said it signed an investigator-initiated study agreement with Belfast Health and Social Care Trust to evaluate ART27.13 in patients with glaucoma or ocular hypertension. The pilot trial is described as a randomized, cross-over study assessing the effects of an oral formulation of ART27.13 on intraocular pressure. Artelo will supply ART27.13 capsules as the investigational medicinal product, while the study is funded by Glaucoma UK and the HSC R&D Division. The protocol has ethics committee and MHRA approvals, and first patient enrollment is anticipated in Q2 2026. No study results have been presented yet; results will be generated in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180741PRIMZONEFULLFEED9673644) on March 18, 2026, and is solely responsible for the information contained therein.